Postplacental LNG-IUD Ultrasound Use Study (PLUS)

Thomas Jefferson University

Status: Unknown

Conditions: IUD Insertion Complication

Treatments: Other: Ultrasound use

Study type: Interventional

Funder types: Other

Identifiers

NCT04474548

20D.502

Details and patient eligibility

About

This study will enroll women planning to have an intrauterine device (IUD) placed for contraception immediately following a vaginal delivery. Women will be randomized to have this procedure done with or without ultrasound guidance. We intend to determine if the routine use of ultrasound to confirm device position reduces the rates of IUD expulsion.

Full description

Participants will be screened and consented for participation in the study when they are admitted to Labor and Delivery for delivery and express desire for a post-placental LNG-IUD. If the patient consents for study participation and meets eligibility criteria above, she will be enrolled in the study after achieving vaginal delivery when she is randomized to either IUD insertion with ultrasound or without ultrasound use. See protocol for detailed description of IUD placement and ultrasound use.

After placement of IUD with or without ultrasound guidance, patients will be scheduled for a routine postpartum follow-up visit 6-10 weeks after delivery. At the postpartum follow-up visit, providers will assess for IUD expulsion with usual clinical practice, including history, pelvic exam, and additional imaging if IUD strings are not visualized on exam. Several attempts to contact participants who do not attend their postpartum visits will be made to attempt to reschedule appointments and conduct a phone questionnaire assessing for IUD expulsion.

Enrollment: 254 estimated patients

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients admitted to Thomas Jefferson University Labor and Delivery who desire and consent to post-placental LNG-IUD placement
• English- and Spanish- speaking patients

Exclusion criteria

• Patients undergoing planned or unplanned Cesarean delivery
• Patients who have an allergy or other contraindication to use of LNG-IUD
• Patients who tested positive for gonorrhea or chlamydia during pregnancy without treatment and a subsequent negative test of cure
• Patients with one or more leiomyomata greater than 3 cm in diameter impinging the uterine cavity
• Clinical diagnosis of chorioamnionitis or presumed chorioamnionitis in labor
• Postpartum hemorrhage as defined by need for transfusion, estimated blood loss greater than 1000mL, or use of 3 or more doses of uterotonic medications

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

254 participants in 2 patient groups

Ultrasound

Experimental group

Description:

For participants randomly assigned to ultrasound use, a bedside ultrasound will be performed using the trans-abdominal probe during and/or immediately after placement of the IUD. The distance from the IUD arms to the fundus will be measured with the ultrasound, and the IUD will be defined as being "in place" when the distance from the top of the IUD to the fundus is measured to be 3mm or less. If the distance is greater than 4mm, the provider may reposition the IUD manually or with a ring forceps.

Treatment:

Other: Ultrasound use

No ultrasound

No Intervention group

Description:

For participants randomly assigned to no ultrasound use, provider will insert the IUD with a ring forceps and will use palpation of the fundus to determine whether or not the IUD is likely in place.